Michelle Lai, MD
Hepatology · Boston, MANPI 1609030865
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,165 of the $6,450 with a category attached, or 95.6%. 4 manufacturers reported payments, led by Madrigal Pharmaceuticals at 56.3% of the total. Reporting peaked in 2024 at $3,632 and has fallen 95.1% since, to $178 in 2025.
Across 7 payments — averaging $921.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$4K
- Intercept Pharmaceuticals, Inc.$3K
- Ipsen Biopharmaceuticals, Inc$134
- Novo Nordisk$44
Across 137 payments — averaging $6338.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$332K
- Intercept Pharmaceuticals, Inc.$192K
- Madrigal Pharmaceuticals$89K
- Pfizer$88K
- AbbVie$62K
- Intercept Pharma Europe Ltd.$55K
- plus $51K from 4 others
What the payments were for
- Speaking & faculty fees$6,16596%
- Travel & lodging$200%
- Food & beverage$2654%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 4 | $3,632 |
| Intercept Pharmaceuticals, Inc. | 1 | $2,640 |
| Ipsen Biopharmaceuticals, Inc | 1 | $134 |
| Novo Nordisk | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hepatology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 14 | $81,343 |
| VemlidyTenofovir Alafenamide | 42 | $61,011 |
| Ursodiol | 86 | $22,744 |
| TrulicityDulaglutide | 11 | $10,418 |
| Azathioprine | 27 | $2,977 |
| Lactulose | 18 | $1,472 |
| Mycophenolate Mofetil | 11 | $1,159 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $996 |
| Omeprazole | 28 | $449 |
| Spironolactone | 12 | $232 |
| Prednisone | 13 | $108 |
| Furosemide | 21 | $101 |
Paid to pharmacies, not to this prescriber.
Other hepatology in Boston
- Nezam AfdhalBoston$332K
- Fredric GordonBoston$284K
- Michael CurryBoston$89K
- Daryl LauBoston$42K
- Zachary FrickerBoston$9K
- Simon RobsonBoston$6K
- Sanjiv ChopraBoston$4K
- Vilas PatwardhanBoston$2K
- Dusanka GrbicBoston$304
- Lauren YangBoston$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.